About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker BMY · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 13, 2026A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherap…
NCT07063745 · Metastatic Non-small Cell Lung Cancer With MTAP Deletion
BMS-986504, Pembrolizumab
BMY
Bristol-Myers Squibb
Phase 2/3Recruiting590Aug 12, 2031Registry ↗
Nov 12, 2026A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
NCT07415031 · Solid Tumors
Adagrasib, Pembrolizumab
BMY
Mirati Therapeutics Inc.
Phase 2Recruiting170Feb 16, 2028Registry ↗
Nov 12, 2026A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolesce…
NCT07288567 · Schizophrenia
KarXT, KarXT Matching Placebo
BMY
Bristol-Myers Squibb
Phase 3Recruiting166Dec 18, 2029Registry ↗
Nov 12, 2026Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Am…
NCT07100080 · Non-Small Cell Lung Cancer
Iza-bren, Carboplatin
BMY
Bristol-Myers Squibb
Phase 2/3Recruiting661Dec 15, 2028Registry ↗
Nov 12, 2026A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer…
NCT06937229 · Alzheimer Disease, Agitation
KarXT, KarX-EC
BMY
Bristol-Myers Squibb
Phase 3Recruiting650Jun 22, 2029Registry ↗
Nov 12, 2026Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects Wit…
NCT05980949 · Psychosis Associated With Alzheimer's Disease
KarXT
BMY
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3Recruiting1,000Sep 7, 2027Registry ↗
Nov 12, 2026A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring Sys…
NCT04446650 · Primary Myelofibrosis
Fedratinib
BMY
Bristol-Myers Squibb
Phase 1/2Completed
was active, not recruiting
31Oct 5, 2023Registry ↗
Nov 10, 2026Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Mo…
NCT07680790 · Non-Small Cell Lung Cancer
Iza-bren, Osimertinib
BMY
Bristol-Myers Squibb
Phase 3Recruiting850Dec 30, 2031Registry ↗
Nov 10, 2026A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Sp…
NCT07285798 · Irritability Associated With Autism Spectrum Disorder
KarXT, KarX-EC
BMY
Bristol-Myers Squibb
Phase 3Recruiting
was not yet recruiting
176Aug 6, 2029Registry ↗
Nov 10, 2026A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism
NCT07284745 · Irritability Associated With Autism Spectrum Disorder
KarXT, KarX-EC
BMY
Bristol-Myers Squibb
Phase 3Recruiting
was not yet recruiting
176Aug 6, 2029Registry ↗
Nov 10, 2026A Study to Evaluate the Effect of KarXT on Urological Safety
NCT07221877 · Schizophrenia
Xanomeline/trospium chloride
BMY
Bristol-Myers Squibb
Phase 4Recruiting60Dec 30, 2027Registry ↗
Nov 10, 2026A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar…
NCT06951711 · Bipolar Disorder Type I With Mania or Mania With Mixed Feat…
KarXT, Placebo
BMY
Bristol-Myers Squibb
Phase 3Recruiting274Nov 2, 2026Registry ↗
Nov 10, 2026A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combinat…
NCT06646276 · Extensive-Stage Small Cell Lung Cancer
BMS-986489 (Atigotatug+Nivolumab), Atezolizumab
BMY
Bristol-Myers Squibb
Phase 3Recruiting530Aug 17, 2027Registry ↗
Nov 9, 2026A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus…
NCT06561386 · Non-small Cell Lung Cancer
Nivolumab, Relatlimab
BMY
Bristol-Myers Squibb
Phase 3Recruiting1,000Jul 30, 2030Registry ↗
Nov 6, 2026A Study to Evaluate the Metabolism, the Routes and Extent of Elimination, and Drug Levels of [14C]N…
NCT07777133 · Healthy Female Participants
Navlimetostat, [14C]Navlimetostat
BMY
Bristol-Myers Squibb
Phase 1Recruiting
was not yet recruiting
6Dec 5, 2026Registry ↗
Nov 6, 2026A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for t…
NCT07424404 · Schizophrenia, Autism-Related Irritability
KarXT, KarX-EC
BMY
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3Recruiting400Mar 8, 2030Registry ↗
Nov 6, 2026A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitati…
NCT07011732 · Alzheimer Disease
Xanomeline/Trospium Chloride Capsule, Xanomeline Enteric Ca…
BMY
Bristol-Myers Squibb
Phase 3Recruiting426Nov 24, 2028Registry ↗
Nov 6, 2026Pan Tumor Rollover Study
NCT03899155 · Cancer
Nivolumab, Ipilimumab
BMY
Bristol-Myers Squibb
Phase 2Recruiting1,500Aug 25, 2029Registry ↗
Nov 5, 2026A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Part…
NCT07361497 · Non-small Cell Lung Cancer (NSCLC)
Pumitamig, Durvalumab
BMY
Bristol-Myers Squibb
Phase 3Recruiting850Sep 18, 2030Registry ↗
Nov 5, 2026A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Ni…
NCT07221149 · Untreated Advanced or Metastatic Gastric, Gastroesophageal…
Pumitamig, Folfox
BMY
Bristol-Myers Squibb
Phase 2/3Recruiting690Nov 8, 2030Registry ↗
Nov 5, 2026Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung…
NCT07024862 · Metastatic Non-small Cell Lung Cancer
nivolumab + ipilimumab
BMY
Bristol-Myers Squibb
—Completed
was active, not recruiting
103Aug 28, 2026Registry ↗
Nov 5, 2026A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in…
NCT07015242 · Lymphoma
Rituximab, Methotrexate
BMY
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2Recruiting65Jan 9, 2028Registry ↗
Nov 5, 2026A Real-World Study of β-Thalassemia Major Treatment With Luspatercept in Taiwan
NCT06596642 · β-Thalassemia Major
Luspatercept
BMY
Bristol-Myers Squibb
—Completed
was active, not recruiting
61Sep 23, 2026Registry ↗
Nov 5, 2026A Rollover Study of CC-122
NCT05688475 · Non-Hodgkin Lymphoma
CC-122, Dexamethasone
BMY
Bristol-Myers Squibb
Phase 1Active, not recruiting12Nov 30, 2026Registry ↗
Nov 4, 2026First-Line Luspatercept in Transfusion-Dependent Lower-Risk Myelodysplastic Neoplasms
NCT07752121 · Myelodysplastic Neoplasms
Luspatercept
BMY
Bristol-Myers Squibb
—Recruiting
was not yet recruiting
190Aug 31, 2030Registry ↗
Nov 4, 2026A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participa…
NCT07492680 · Solid Tumors
Navlimetostat, Daraxonrasib
BMY
Bristol-Myers Squibb
Phase 2Recruiting254Aug 15, 2028Registry ↗
Nov 3, 2026A Study to Assess the Relative Bioavailability of Irafamdastat (BMS-986368) and to Assess the Food…
NCT07837115 · Healthy Volunteers
Irafamdastat
BMY
Celgene
Phase 1Recruiting
was not yet recruiting
24Dec 19, 2026Registry ↗
Nov 3, 2026A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or…
NCT07140913 · Mania, Bipolar Disorder
Xanomeline/Trospium Chloride, Placebo
BMY
Bristol-Myers Squibb
Phase 3Recruiting424Jun 28, 2027Registry ↗
Nov 3, 2026A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitati…
NCT07011745 · Alzheimer's Disease
Xanomeline/Trospium Chloride Capsule, Xanomeline Enteric Ca…
BMY
Bristol-Myers Squibb
Phase 3Recruiting426Nov 3, 2028Registry ↗
Nov 2, 2026Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
NCT07379827 · Schizophrenia
Xanomeline and trospium chloride (KarXT)
BMY
Bristol-Myers Squibb
—Recruiting1,500Jun 20, 2028Registry ↗
Nov 2, 2026A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hyp…
NCT07361289 · Hypertrophic Cardiomyopathy
Mavacamten
BMY
Bristol-Myers Squibb
—Recruiting500Aug 22, 2028Registry ↗
Nov 2, 2026Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy
NCT07256015 · Psoriasis
Deucravacitinib
BMY
Bristol-Myers Squibb
—Active, not recruiting
was recruiting
200Jul 5, 2027Registry ↗
Nov 2, 2026Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Ca…
NCT07215962 · Non-small Cell Lung Cancer (NSCLC)
Nivolumab + ipilimumab, Nivolumab + ipilimumab + platinum-b…
BMY
Bristol-Myers Squibb
—Completed
was active, not recruiting
300Jul 1, 2025Registry ↗
Nov 2, 2026A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucoc…
NCT07175285 · Systemic Lupus Erythematosus (SLE)
Current standard of care treatment options
BMY
Bristol-Myers Squibb
—Recruiting223Mar 24, 2028Registry ↗
Nov 2, 2026A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participan…
NCT06882785 · Schizophrenia
KarXT, Placebo
BMY
Bristol-Myers Squibb
Phase 3Recruiting250Sep 23, 2028Registry ↗
Nov 2, 2026Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (B…
NCT06268886 · Alzheimer Disease, Early Onset
BMS-986446, Placebo
BMY
Bristol-Myers Squibb
Phase 2Active, not recruiting310Dec 17, 2026Registry ↗
Nov 2, 2026Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
NCT03435796 · Neoplasms
Gene-modified (GM) T cell therapy
BMY
Celgene
Phase 2/3Recruiting1,541May 29, 2043Registry ↗
Nov 2, 2026Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the…
NCT03036098 · Urothelial Cancer
Nivolumab, Ipilimumab
BMY
Bristol-Myers Squibb
Phase 3Completed
was active, not recruiting
1,314Aug 30, 2024Registry ↗
Oct 30, 2026Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
NCT07686263 · Schizophrenia
Xanomeline/Trospium Chloride, Placebo
BMY
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3Recruiting472Mar 3, 2029Registry ↗
Oct 30, 2026Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With P…
NCT07441408 · Pulmonary Fibrosis
BMS-986278
BMY
Bristol-Myers Squibb
Phase 3Not yet recruiting2,380Nov 22, 2029Registry ↗
Oct 30, 2026A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezo…
NCT05519085 · Relapsed or Refractory Multiple Myeloma
mezigdomide, Pomalidomide
BMY
Celgene
Phase 3Recruiting810Jan 10, 2027Registry ↗
Oct 30, 2026Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of…
NCT04613596 · Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small C…
Adagrasib, Adagrasib
BMY
Mirati Therapeutics Inc.
Phase 2/3Recruiting626Oct 31, 2028Registry ↗
Oct 29, 2026A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Particip…
NCT06615479 · Relapsed or Refractory Multiple Myeloma (RRMM)
BMS-986393, Cyclophosphamide
BMY
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3Recruiting440Dec 30, 2027Registry ↗
Oct 28, 2026Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMA…
NCT07116967 · Plaque Psoriasis
Deucravacitinib, Ustekinumab
BMY
Bristol-Myers Squibb
Phase 3Recruiting3,040Jan 16, 2031Registry ↗
Oct 28, 2026A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum…
NCT05613088 · Neoplasms, Ovarian
MORAb-202, Paclitaxel
BMY
Bristol-Myers Squibb
Phase 2Terminated106Jun 17, 2024Registry ↗
Oct 27, 2026A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adoles…
NCT06979453 · Plaque Psoriasis
Deucravacitinib, Placebo
BMY
Bristol-Myers Squibb
Phase 3Recruiting366Oct 12, 2029Registry ↗
Oct 27, 2026A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheime…
NCT06976216 · Alzheimer's Disease
KarXT, KarX-EC
BMY
Bristol-Myers Squibb
Phase 3Recruiting586Sep 11, 2028Registry ↗
Oct 27, 2026A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemo…
NCT06875310 · Carcinoma, Non-Small-Cell Lung
Adagrasib, Pembrolizumab
BMY
Mirati Therapeutics Inc.
Phase 3Recruiting630Sep 7, 2029Registry ↗
Oct 27, 2026A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multip…
NCT06782490 · Multiple Sclerosis Spasticity
BMS-986368, Placebo
BMY
Celgene
Phase 2Recruiting200May 26, 2027Registry ↗
Oct 27, 2026A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
NCT06585787 · Alzheimer Disease
KarXT, Placebo
BMY
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3Recruiting406Nov 24, 2026Registry ↗

The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:55 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances